Michel Marty

Summary

Country: France

Publications

  1. ncbi Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors
    Catherine Delbaldo
    Department of Medical Oncology, Beaujon University Hospital, Clichy, France
    Invest New Drugs 26:35-43. 2008
  2. ncbi Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group
    Michel Marty
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 23:4265-74. 2005
  3. ncbi The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab
    Michel Marty
    Centre for Therapeutic Innovations in Oncology and Haematology, Saint Louis University Hospital, 1 avenue Claude Vellefaux, 75010 Paris, France
    Eur J Cancer 44:912-20. 2008
  4. ncbi Chemotherapy for metastatic breast cancer-report of a European expert panel
    John Crown
    Vincent s University Hospital, Dublin, Ireland
    Lancet Oncol 3:719-27. 2002
  5. pmc NF-kappa B genes have a major role in inflammatory breast cancer
    Florence Lerebours
    Centre Rene Huguenin, FNCLCC, 35 rue Dailly, 92210, St Cloud, France
    BMC Cancer 8:41. 2008
  6. ncbi Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE)
    Jean Yves Blay
    Hopital Edouard Herriot, Oncologie Médicale, Pavillon E, 5 Place d Arsonval, 69437 Lyon Cedex 03, France
    Crit Rev Oncol Hematol 64:106-14. 2007
  7. pmc Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen
    Philippe Bertheau
    Laboratoire de Pathologie, Assistance Publique Hopitaux de Paris, Hopital Saint Louis, Paris, France
    PLoS Med 4:e90. 2007
  8. ncbi The evolution of EMEA
    Michel Marty
    Eur J Cancer 41:2037. 2005
  9. ncbi Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer
    Philippe Bertheau
    Service de Pathologie, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75010 Paris, France
    Oncol Rep 14:513-20. 2005
  10. ncbi Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature
    Ivan Bieche
    Laboratoire d Oncogénétique INSERM E0017, Centre Rene Huguenin, St Cloud, France
    Clin Cancer Res 10:6789-95. 2004

Collaborators

Detail Information

Publications13

  1. ncbi Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors
    Catherine Delbaldo
    Department of Medical Oncology, Beaujon University Hospital, Clichy, France
    Invest New Drugs 26:35-43. 2008
    ..Etaracizumab was well-tolerated at doses up to 6 mg/kg with no evidence of immunogenicity. The safety profile of etaracizumab warrants further exploration in ongoing phase I/II trials...
  2. ncbi Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group
    Michel Marty
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 23:4265-74. 2005
    ..This randomized, multicenter trial compared first-line trastuzumab plus docetaxel versus docetaxel alone in patients with human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC)...
  3. ncbi The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab
    Michel Marty
    Centre for Therapeutic Innovations in Oncology and Haematology, Saint Louis University Hospital, 1 avenue Claude Vellefaux, 75010 Paris, France
    Eur J Cancer 44:912-20. 2008
    ..Future potential uses of bevacizumab in breast cancer are introduced...
  4. ncbi Chemotherapy for metastatic breast cancer-report of a European expert panel
    John Crown
    Vincent s University Hospital, Dublin, Ireland
    Lancet Oncol 3:719-27. 2002
    ..Novel oral therapies have now been developed and are being used increasingly in patients whose disease has progressed following taxane therapy...
  5. pmc NF-kappa B genes have a major role in inflammatory breast cancer
    Florence Lerebours
    Centre Rene Huguenin, FNCLCC, 35 rue Dailly, 92210, St Cloud, France
    BMC Cancer 8:41. 2008
    ..Given the role of NF-kappaB-related genes in cell proliferation, invasiveness, angiogenesis and inflammation, we postulated that they might be deregulated in IBC...
  6. ncbi Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE)
    Jean Yves Blay
    Hopital Edouard Herriot, Oncologie Médicale, Pavillon E, 5 Place d Arsonval, 69437 Lyon Cedex 03, France
    Crit Rev Oncol Hematol 64:106-14. 2007
    ....
  7. pmc Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen
    Philippe Bertheau
    Laboratoire de Pathologie, Assistance Publique Hopitaux de Paris, Hopital Saint Louis, Paris, France
    PLoS Med 4:e90. 2007
    ..Breast cancers with a TP53 mutation were repeatedly shown to have a poor outcome, but whether this reflects poor response to treatment or greater intrinsic aggressiveness of the tumor is unknown...
  8. ncbi The evolution of EMEA
    Michel Marty
    Eur J Cancer 41:2037. 2005
  9. ncbi Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer
    Philippe Bertheau
    Service de Pathologie, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75010 Paris, France
    Oncol Rep 14:513-20. 2005
    ..In conclusion, in 108 stage IIB to IIIB breast cancer patients initially treated by high-dose chemotherapy, combined grading of clinical and pathologic responses in a single score allowed accurate prediction of outcome...
  10. ncbi Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature
    Ivan Bieche
    Laboratoire d Oncogénétique INSERM E0017, Centre Rene Huguenin, St Cloud, France
    Clin Cancer Res 10:6789-95. 2004
    ..Inflammatory breast cancer (IBC) is a rare but particularly aggressive form of primary breast cancer. The molecular mechanisms responsible for IBC are largely unknown...
  11. ncbi Two prognostic groups of inflammatory breast cancer have distinct genotypes
    Florence Lerebours
    Institut National de la Santé et de la Recherche Médicale INSERM E0017 Oncogénétique, Centre Rene Huguenin, 35 rue Dailly, F 92211 St Cloud, France
    Clin Cancer Res 9:4184-9. 2003
    ..Analysis of loss of heterozygosity (LOH) can provide a molecular portrait of the genetic alterations underlying stepwise cancer progression. We tested the value of LOH patterns as diagnostic and prognostic markers in IBC...
  12. ncbi Evidence of chromosome regions and gene involvement in inflammatory breast cancer
    Florence Lerebours
    Inserm E0017 oncogénétique, St Cloud, France
    Int J Cancer 102:618-22. 2002
    ..In contrast, the DNA amplification levels of ERBB2, MYC and CCND1, as measured by real-time quantitative PCR, did not differ between IBC and non IBC...
  13. ncbi Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer
    Elizabeth Turpin
    Service de Biochimie B and CNRS UPR9051, Hopital Saint Louis, 1, avenue Claude Vellefaux, F 75475 Paris Cedex 10, France
    Oncogene 21:7593-7. 2002
    ..Given the importance of TP53 and ERBB2 in the response to treatments, our observations have important therapeutic implications for the clinical management of IBC patients...